3 Cash-Producing Stocks We Approach with Caution

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Cash flow is valuable, but it’s not everything - StockStory helps you identify the companies that truly put it to work. Keeping that in mind, here are three cash-producing companies to steer clear of and a few better alternatives.

H&R Block (HRB)

Trailing 12-Month Free Cash Flow Margin: 13.8%

Founded in 1955 by brothers Henry W. Bloch and Richard A. Bloch, H&R Block (NYSE:HRB) is a tax preparation company offering professional tax assistance and financial solutions to individuals and small businesses.

Why Do We Steer Clear of HRB?

1. Muted 5.6% annual revenue growth over the last five years shows its demand lagged behind its consumer discretionary peers
2. Eroding returns on capital suggest its historical profit centers are aging

At $31.63 per share, H&R Block trades at 1x forward price-to-sales. Dive into our free research report to see why there are better opportunities than HRB.

Exact Sciences (EXAS)

Trailing 12-Month Free Cash Flow Margin: 11%

With a mission to detect cancer earlier when it's more treatable, Exact Sciences (NASDAQ:EXAS) develops and markets cancer screening and diagnostic tests, including its flagship Cologuard stool-based colorectal cancer screening test.

Why Does EXAS Worry Us?

1. Cash-burning history makes us doubt the long-term viability of its business model
2. Negative returns on capital show that some of its growth strategies have backfired

Exact Sciences is trading at $103.47 per share, or 90.8x forward P/E. Check out our free in-depth research report to learn more about why EXAS doesn’t pass our bar.

Penumbra (PEN)

Trailing 12-Month Free Cash Flow Margin: 12.5%

Founded in 2004 to address challenging medical conditions with significant unmet needs, Penumbra (NYSE:PEN) develops and manufactures innovative medical devices for treating vascular diseases and providing immersive healthcare rehabilitation solutions.

Why Does PEN Give Us Pause?

1. Smaller revenue base of $1.40 billion means it hasn’t achieved the economies of scale that some industry juggernauts enjoy
2. Below-average returns on capital indicate management struggled to find compelling investment opportunities

Penumbra’s stock price of $340.96 implies a valuation ratio of 67.2x forward P/E. To fully understand why you should be careful with PEN, check out our full research report (it’s free).

Stocks We Like More

ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.

Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.